A Study of Two Different Formulations of LY3502970 in Healthy Participants

NCT05341089 · Completed

Last updated 2026-05-28

This study is testing two different versions of the drug LY3502970 in healthy adults to compare how the body absorbs and processes each version.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 39 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2022-05 · est. completion 2022-09

Where 1 site · Singapore

What this study is testing ClinicalTrials.gov NCT05341089 ↗

Description as written by the study sponsor.

The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream when administered as two different formulations in healthy participants. The study will also evaluate the safety and tolerability of LY3502970. The study will last up to 13 weeks excluding the screening period.

Treatments tested

LY3502970 Drug

Administered orally.

Main thing measured	Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05341089 ↗